Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant huntingtin toxicity

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Xifró, Xavier ^a,b,c,d   Anglada Huguet, Marta ^a,b,c   Rué, Laura ^a,b,c   Saavedra, Ana ^a,b,c   Pérez Navarro, Esther ^a,b,c   Alberch, Jordi ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d UNIVERSITY OF GIRONA   (Spain)

Author keywords

cell death; ERK; Huntington's disease; knock in mouse; neuroprotection; PDK1; R6 1 mouse; striatum

Indexed keywords

RIBOSOMAL S6 KINASE 1; RIBOSOMAL S6 KINASE 2; S6 KINASE; UNCLASSIFIED DRUG; HUNTINGTON PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE PROTEIN; NUCLEAR PROTEIN; RIBOSOMAL PROTEIN S6 KINASE, 90KDA, POLYPEPTIDE 3; RPS6KA1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; CYTOSOL; ENZYME PHOSPHORYLATION; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; CELL CULTURE; CYTOLOGY; FEMALE; GENETICS; MALE; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE;

MUS;

ANIMALS; CELLS, CULTURED; CORPUS STRIATUM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 80055019089     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-74     Document Type: Article

References (43)

1. The RSK family of kinases: emerging roles in cellular signaling. Anjum R, Blenis J, Nat Rev Mol Cell Biol 2008 9 747 758 10.1038/nrm2509 18813292
2. Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Chen RH, Sarnecki C, Blenis J, Mol Cell Biol 1992 12 915 927 1545823
3. 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1. Jensen CJ, Buch MB, Krag TO, Hemmings BA, Gammeltoft S, Frödin M, J Biol Chem 1999 274 27168 27176 10.1074/jbc.274.38.27168 10480933 (Pubitemid 29440065)
4. Role and regulation of 90-kDa ribosomal S6 kinase (RSK) in signal transduction. Frödin M, Gammeltoft S, Mol Cell Endocrinol 1999 151 65 77 10.1016/S0303-7207(99)00061-1 10411321 (Pubitemid 29295514)
5. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. Tan Y, Ruan H, Demeter MR, Comb MJ, J Biol Chem 1999 274 34859 34867 10.1074/jbc.274.49.34859 10574959 (Pubitemid 129509532)
6. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Sutherland C, Leighton IA, Cohen P, Biochem J 1993 296 15 19 8250835 (Pubitemid 23344723)
7. The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Anjum R, Roux PP, Ballif BA, Gygi SP, Blenis J, Curr Biol 2005 15 1762 1767 10.1016/j.cub.2005.08.050 16213824 (Pubitemid 41415634)
8. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Xing J, Ginty DD, Greenberg ME, Science 1996 273 959 963 10.1126/science.273.5277.959 8688081 (Pubitemid 26275173)
9. A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. Rivera VM, Miranti CK, Misra RP, Ginty DD, Chen RH, Blenis J, Greenberg ME, Mol Cell Biol 1993 13 6260 6273 8413226 (Pubitemid 23292620)
10. The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaB alpha and stimulates its degradation in vitro. Ghoda L, Lin X, Greene WC, J Biol Chem 1997 272 21281 21288 10.1074/jbc.272.34. 21281 9261139 (Pubitemid 27373994)
11. IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. Schouten GJ, Vertegaal AC, Whiteside ST, Isral A, Toebes M, Dorsman JC, van der EB AJ, Zantema A, EMBO J 1997 16 3133 3144 10.1093/emboj/16.11.3133 9214631 (Pubitemid 27234953)
12. Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB. Ginty DD, Bonni A, Greenberg ME, Cell 1994 77 713 725 10.1016/0092-8674(94)90055-8 8205620 (Pubitemid 24175607)
13. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME, Science 1999 286 1358 1362 10.1126/science.286.5443.1358 10558990 (Pubitemid 29535895)
14. Requirement of 3-phosphoinositide-dependent protein kinase-1 for BDNF-mediated neuronal survival. Kharebava G, Makonchuk D, Kalita KB, Zheng JJ, Hetman M, J Neurosci 2008 28 11409 11420 10.1523/JNEUROSCI.2135-08.2008 18971483
15. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative Research Group, Cell 1993 72 971 983 10.1016/0092-8674(93)90585-E 8458085 (Pubitemid 23110238)
16. Differential loss of striatal projection neurons in Huntington disease. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB, Proc Natl Acad Sci USA 1998 85 5733 5737
17. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME, J Biol Chem 2003 278 50514 50522 10.1074/jbc.M309348200 14522959 (Pubitemid 37548897)
18. Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression. Gines S, Paoletti P, Alberch J, J Biol Chem 2010 285 21537 21548 10.1074/jbc.M109.084202 20442398
19. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, Marsh JL, Hum Molec Genet 2011 20 261 270 10.1093/hmg/ddq460 20952447
20. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. Scotter EL, Goodfellow CE, Graham ES, Dragunow M, Glass M, Br J Pharmacol 2010 160 747 761 10.1111/j.1476-5381.2010.00773.x 20590577
21. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM, Hum Molec Genet 2006 15 273 285 16330479 (Pubitemid 43125981)
22. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP, Cell 1996 87 493 506 10.1016/S0092-8674(00) 81369-0 8898202 (Pubitemid 26374323)
23. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier L, Cohen P, Alessi DR, Biochem J 2007 401 29 38 10.1042/BJ20061088 17040210 (Pubitemid 46114597)
24. Knock-in mouse models of Huntington's disease. Menalled LB, NeuroRx 2005 2 465 470 10.1602/neurorx.2.3.465 16389309 (Pubitemid 41444879)
25. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A, Duyao MA, Vrbanac V, Weaver M, Gusella JF, Joyner AL, MacDonald ME, Hum Molec Genet 1999 8 115 122 10.1093/hmg/8.1.115 9887339 (Pubitemid 29039056)
26. Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice. Fossale E, Wheeler WC, Vrbanac V, Lebel LA, Teed A, Mysore JS, Gusella JF, MacDonald ME, Persichetti E, Hum Molec Genet 2002 11 2233 2241 10.1093/hmg/11.19.2233 12217951
27. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT, Nat Neurosci 2002 5 731 736 12089530 (Pubitemid 34827590)
28. Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease. Perez-Navarro E, Canals JM, Gines S, Alberch J, Histol Histopathol 2006 21 1217 1232 16874665 (Pubitemid 44614504)
29. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheller VC, Sharp AH, Persichetti F, Cattaneo E, MacDonald ME, Hum Molec Genet 2000 9 2799 2809 10.1093/hmg/9.19.2799 11092756
30. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Humbert S, Bryson EA, Cordelières FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F, Dev Cell 2002 2 831 837 10.1016/S1534-5807(02)00188-0 12062094 (Pubitemid 34650078)
31. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. Saavedra A, García-Mártinez JM, Xifrá X, Giralt A, Torres-Peraza JF, Canals JM, Díaz-Hernandez M, Lucas JJ, Alberch J, Pérez-Navarro E, Cell Death Differ 2010 17 324 335 10.1038/cdd.2009.127 19745829
32. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Rangone H, Poizat G, Troncoso J, Ross CA, MacDonald ME, Saudou F, Humbert S, Eur J Neurosci 2004 19 273 279 10.1111/j.0953-816X.2003.03131.x 14725621 (Pubitemid 38177866)
33. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Choen MS, Hadjivassiliou H, Taunton J, Nat Chem Biol 2007 3 156 160 10.1038/nchembio859 17259979
34. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Williams MR, Arthur JS, Balendran A, van der Kaay J, Poli V, Cohen P, Alessi DR, Curr Biol 2000 10 439 448 10.1016/S0960-9822(00)00441-3 10801415 (Pubitemid 30247331)
35. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E, Science 2001 293 445 446 10.1126/science.1063429 11463904 (Pubitemid 32679063)
36. Brain-derived neurotrophic factor in neurodegenerative diseases. Zuccato C, Cattaneo E, Nat Rev Neurol 2009 5 311 322 10.1038/nrneurol.2009.54 19498435
37. Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. De Cesare D, Jacquot S, Hanauer A, Sassone-Corsi P, Proc Natl Acad Sci USA 1998 95 12202 12207 10.1073/pnas.95.21.12202 9770464 (Pubitemid 28483743)
38. Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Giralt A, Rodrigo TM, Martin ED, Gonzalez JR, Mila M, Cẽa V, Dierssen M, Canals JM, Alberch J, Neuroscience 2009 158 1234 1250 10.1016/j.neuroscience.2008.11.024 19121372
39. Immortalized GABAergic cell lines derived from rat striatum using a temperature-sensitive allele of the SV40 large T antigen. Giordano M, Takashima H, Herranz A, Polotorak M, Geller HM, Marone M, Freed WJ, Exp Neurol 1993 124 395 400 10.1006/exnr.1993.1213 8287936 (Pubitemid 24041790)
40. Brain-derived neurotrophic factor (BDNF) mediates bone morphogenetic protein-2 (BMP-2) effects on cultured striatal neurones. Gratacos E, Checa N, Perez-Navarro E, Alberch J, J Neurochem 2001 79 747 755 11723167 (Pubitemid 33086512)
41. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. Xifro X, Garcia-Martinez JM, del Toro D, Alberch J, Perez-Navarro E, J Neurochem 2008 105 1596 1612 10.1111/j.1471-4159.2008.05252.x 18221365 (Pubitemid 351678484)
42. Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. Del Toro D, Canals JM, Gines S, Kojima M, Egea G, Alberch J, J Neurosci 2006 26 12748 12757 10.1523/JNEUROSCI.3873-06.2006 17151278 (Pubitemid 44904570)
43. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth. Sapkota GP, Kieloch A, Lizcano JM, Lain S, Arthur JS, Williams MR, Morrice N, Deak M, Alessi DR, J Biol Chem 2001 276 19469 19482 10.1074/jbc.M009953200 11297520